Clinical trial of bromhexine in Sjogren's syndrome

R. Avisar, H. Savir, I. Machtey, L. Ovaknin, P. Shaked, R. Menache, D. Allalouf

Research output: Contribution to journalArticlepeer-review


Tear secretion and lysozyme tear content were measured in 30 patients with Sjogren's syndrome after treatment with oral bromhexine, 32 mg/day. In 21 patients (70%) there was a marked increase in tear secretion and in lysozyme content. In patients with keratoconjunctivitis sicca (KCS) good results in clarifying the mucoid eye discharge were obtained. A remarkable amelioration of xerostomia was also noted. Six other patients, serving as controls, were given a placebo and bromhexine. The placebo had no influence on the rate of tear secretion, while bromhexine caused it to increase in 70% of the controls. The side effects of bromhexine treatment encountered in the present study were negligible and transient. We consider bromhexine to be the drug of choice in the treatment of Sjogren's syndrome.

Original languageEnglish
Pages (from-to)971-973
Number of pages3
JournalAnnals of Ophthalmology
Issue number8
StatePublished - 1981
Externally publishedYes


Dive into the research topics of 'Clinical trial of bromhexine in Sjogren's syndrome'. Together they form a unique fingerprint.

Cite this